Form 4: Vaxcyte CEO Grant Pickering Executes Stock Options and Sells Shares

Grant Pickering, CEO of Vaxcyte, Inc., exercised stock options and sold shares of common stock on February 23 and 26, 2024, according to a Form 4 filing with the SEC.

Summary

• Grant Pickering, the CEO of Vaxcyte, Inc., engaged in transactions involving the company's stock on February 23 and 26, 2024.
• He exercised stock options to acquire 15,000 shares on February 23 and 30,000 shares on February 26 at a price of $1.79 per share.
• Concurrently, Pickering sold shares of common stock on the same days at varying weighted-average prices.
• On February 23, sales occurred at prices ranging from $74.45 to $77.56, and on February 26, shares were sold at approximately $79.03.
• Following these transactions, Pickering directly owns 375,814 shares of common stock.
• He also indirectly owns 149,978 shares through a children's trust for his daughter and 149,978 shares through a children's trust for his son.
• Pickering also holds options to buy 30,225 shares.

Sentiment

Score: 5

Explanation: Neutral. This is a standard SEC filing detailing insider transactions. The CEO is exercising options and selling shares, which is not inherently positive or negative.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares for personal financial management. The market will likely interpret this based on the overall volume and context of Vaxcyte's performance.

Comparison to Industry Standards

• Executive stock option exercises and sales are a common practice in publicly traded companies, particularly in the biotechnology sector.
• The use of 10b5-1 trading plans, as indicated in the filing, is a standard method for insiders to sell shares while mitigating concerns about trading on non-public information.
• Comparable companies like Moderna (MRNA) and BioNTech (BNTX) also see regular Form 4 filings from their executives detailing similar transactions.

Stakeholder Impact

• The transactions could have a minor impact on shareholders depending on how the market interprets the CEO's stock sales.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates